MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

NCT00868595 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Castrate Resistant Prostate Cancer (CRPC)

Interventions

BIOLOGICAL: BPX-101
DRUG: AP1903

Sponsor

Bellicum Pharmaceuticals

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]